Caseware UK (AP4) 2025.0.111 2025.0.111 2025-12-312025-12-31The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.true62025-01-01falseNo description of principal activity10truefalse 11669397 2025-01-01 2025-12-31 11669397 2024-01-01 2024-12-31 11669397 2025-12-31 11669397 2024-12-31 11669397 2024-01-01 11669397 c:Director3 2025-01-01 2025-12-31 11669397 d:Buildings 2025-01-01 2025-12-31 11669397 d:Buildings 2025-12-31 11669397 d:Buildings 2024-12-31 11669397 d:Buildings d:OwnedOrFreeholdAssets 2025-01-01 2025-12-31 11669397 d:OfficeEquipment 2025-01-01 2025-12-31 11669397 d:OfficeEquipment 2025-12-31 11669397 d:OfficeEquipment 2024-12-31 11669397 d:OfficeEquipment d:OwnedOrFreeholdAssets 2025-01-01 2025-12-31 11669397 d:ComputerEquipment 2025-01-01 2025-12-31 11669397 d:ComputerEquipment 2025-12-31 11669397 d:ComputerEquipment 2024-12-31 11669397 d:ComputerEquipment d:OwnedOrFreeholdAssets 2025-01-01 2025-12-31 11669397 d:OwnedOrFreeholdAssets 2025-01-01 2025-12-31 11669397 d:CurrentFinancialInstruments 2025-12-31 11669397 d:CurrentFinancialInstruments 2024-12-31 11669397 d:CurrentFinancialInstruments d:WithinOneYear 2025-12-31 11669397 d:CurrentFinancialInstruments d:WithinOneYear 2024-12-31 11669397 d:ShareCapital 2025-12-31 11669397 d:ShareCapital 2024-12-31 11669397 d:SharePremium 2025-12-31 11669397 d:SharePremium 2024-12-31 11669397 d:OtherMiscellaneousReserve 2025-12-31 11669397 d:OtherMiscellaneousReserve 2024-12-31 11669397 d:RetainedEarningsAccumulatedLosses 2025-12-31 11669397 d:RetainedEarningsAccumulatedLosses 2024-12-31 11669397 c:OrdinaryShareClass1 2025-01-01 2025-12-31 11669397 c:OrdinaryShareClass1 2025-12-31 11669397 c:OrdinaryShareClass1 2024-12-31 11669397 c:OrdinaryShareClass3 2025-01-01 2025-12-31 11669397 c:OrdinaryShareClass3 2025-12-31 11669397 c:OrdinaryShareClass3 2024-12-31 11669397 c:FRS102 2025-01-01 2025-12-31 11669397 c:AuditExempt-NoAccountantsReport 2025-01-01 2025-12-31 11669397 c:FullAccounts 2025-01-01 2025-12-31 11669397 c:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 11669397 e:PoundSterling 2025-01-01 2025-12-31 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 11669397










ECHOPOINT MEDICAL LTD








UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 DECEMBER 2025



 
ECHOPOINT MEDICAL LTD
REGISTERED NUMBER: 11669397

BALANCE SHEET
AS AT 31 DECEMBER 2025

As restated
2025
2024
Note
£
£

Fixed assets
  

Tangible assets
 4 
32,980
27,633

Investments
 5 
81
-

  
33,061
27,633

Current assets
  

Debtors: amounts falling due within one year
 6 
359,339
183,986

Cash at bank and in hand
 7 
1,673,111
3,314,083

  
2,032,450
3,498,069

Creditors: amounts falling due within one year
 8 
(158,287)
(158,448)

Net current assets
  
 
 
1,874,163
 
 
3,339,621

Total assets less current liabilities
  
1,907,224
3,367,254

  

Net assets
  
1,907,224
3,367,254


Capital and reserves
  

Called up share capital 
 9 
50
48

Share premium account
  
7,036,402
6,726,183

Share-based payment reserve
  
968,010
194,290

Profit and loss account
  
(6,097,238)
(3,553,267)

  
1,907,224
3,367,254


Page 1

 
ECHOPOINT MEDICAL LTD
REGISTERED NUMBER: 11669397

BALANCE SHEET (CONTINUED)
AS AT 31 DECEMBER 2025

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 

A R Odell
Director

Date: 3 August 2026

The notes on pages 3 to 9 form part of these financial statements.

Page 2

 
ECHOPOINT MEDICAL LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

1.


General information

Echopoint Medical Ltd is a private company limited by share capital and incorporated in England and Wales. The registered office is 2nd Floor 65-69 East Road, London, England, N1 6AH.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies.

The following principal accounting policies have been applied:

 
2.2

Going concern

The directors have considered the Company's financial position and, following investment received in February 2026, believe that preparing the financial statements on a going concern basis remains appropriate. 

 
2.3

Foreign currency translation

Functional and presentation currency

The Company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges.

Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the Statement of Comprehensive Income within 'finance income or costs'. All other foreign exchange gains and losses are presented in profit or loss within 'other operating income'.

Page 3

 
ECHOPOINT MEDICAL LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

2.Accounting policies (continued)

 
2.4

Research and development

In the research phase of an internal project it is not possible to demonstrate that the project will generate future economic benefits and hence all expenditure on research shall be recognised as an expense when it is incurred. Intangible assets are recognised from the development phase of a project if and only if certain specific criteria are met in order to demonstrate the asset will generate probable future economic benefits and that its cost can be reliably measured. The capitalised development costs are subsequently amortised on a straight-line basis over their useful economic lives, which range from 3 to 6 years.

If it is not possible to distinguish between the research phase and the development phase of an internal project, the expenditure is treated as if it were all incurred in the research phase only.

 
2.5

Government grants

Grants are accounted for under the accruals model as permitted by FRS 102. Grants relating to expenditure on tangible fixed assets are credited to profit or loss at the same rate as the depreciation on the assets to which the grant relates. The deferred element of grants is included in creditors as deferred income.

Grants of a revenue nature are recognised in the Statement of Comprehensive Income in the same period as the related expenditure.

 
2.6

Pensions

Defined contribution pension plan

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Balance Sheet. The assets of the plan are held separately from the Company in independently administered funds.

 
2.7

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.


 
2.8

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Page 4

 
ECHOPOINT MEDICAL LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

2.Accounting policies (continued)


2.8
Tangible fixed assets (continued)

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Leasehold improvements
-
33%
Office equipment
-
33%
Computer equipment
-
33%

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.9

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.10

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.11

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.


3.


Employees

The average monthly number of employees, including directors, during the year was 10 (2024 - 6).

Page 5

 
ECHOPOINT MEDICAL LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

4.


Tangible fixed assets


Leasehold improvements
Office equipment
Computer equipment
Total

£
£
£
£



Cost or valuation


At 1 January 2025
11,541
20,585
19,371
51,497


Additions
-
6,575
12,250
18,825



At 31 December 2025

11,541
27,160
31,621
70,322



Depreciation


At 1 January 2025
1,511
8,690
13,663
23,864


Charge for the year on owned assets
3,847
5,634
3,997
13,478



At 31 December 2025

5,358
14,324
17,660
37,342



Net book value



At 31 December 2025
6,183
12,836
13,961
32,980



At 31 December 2024
10,030
11,895
5,708
27,633


5.


Fixed asset investments





Unlisted investments

£



Cost or valuation


Additions
81



At 31 December 2025
81





6.


Debtors

2025
2024
£
£


Other debtors
157,991
33,003

Prepayments and accrued income
84,805
19,148

Tax recoverable
116,543
131,835

359,339
183,986


Page 6

 
ECHOPOINT MEDICAL LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

7.


Cash and cash equivalents

2025
2024
£
£

Cash at bank and in hand
1,673,111
3,314,083

1,673,111
3,314,083



8.


Creditors: Amounts falling due within one year

2025
2024
£
£

Trade creditors
83,684
68,139

Other taxation and social security
30,152
15,399

Other creditors
8,973
3,094

Accruals and deferred income
35,478
71,816

158,287
158,448



9.


Share capital

2025
2024
£
£
Allotted, called up and fully paid



254,517 (2024 - 250,349) Ordinary shares of £0.0001 each
25
25
247,815 (2024 - 233,800) Ordinary B shares of £0.0001 each
25
23

50

48


During the year 14,015 B Ordinary shares of £0.0001 were issued for a total consideration of £285,213.

During the year 4,168 Ordinary shares of £0.0001 were issued for a total consideration of £25,008.

Page 7

 
ECHOPOINT MEDICAL LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

10.


Share-based payments

During the year, the Company granted both unapproved and EMI share options.

Weighted average exercise price (pence)
2025
Number
2025
Weighted average exercise price
(pence)
2024
Number
2024

Outstanding at the beginning of the year


77,600

 
-
 
Granted during the year

499

36,300

600
 
77,600
 
Forfeited during the year

600

(5,832)

 
-
 
Exercised during the year

600

(4,168)

 
-
 
Outstanding at the end of the year
422

103,900

600
 
77,600
 

2025
2024

Option pricing model used


Black-Scholes

Black-Scholes
 
Weighted average share price (pence)


422

600
 
Exercise price (pence)


499

600
 
Weighted average contractual life (days)


1,095

1,095
 
Expected volatility


20.3%

20.3%
 
Risk-free interest rate


4.055%

4.034%
 

2025
2024
£
£


Equity-settled schemes
843,259
194,290

843,259
194,290


11.


Prior year adjustment

A prior year adjustment of £194,290 has been posted to account for the share-based payment charge in respect of share options granted in the prior year. The profit and loss acount decreased by £194,290 and a share-based payment reserve was created with a corresponding entry.


12.


Pension commitments

The Company operates a defined contribution pension scheme. The assets of the scheme are held
separately from those of the Company in an independently administered fund. The pension cost charge
represents contributions payable by the Company to the fund and amounted to £6,263 (2024: £4,229).

Page 8

 
ECHOPOINT MEDICAL LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

13.


Controlling party

The Company is controlled by its directors.


Page 9